| Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer A Vaishnavi, M Capelletti, AT Le, S Kako, M Butaney, D Ercan, S Mahale, ... Nature medicine 19 (11), 1469-1472, 2013 | 686 | 2013 |
| TRKing down an old oncogene in a new era of targeted therapy A Vaishnavi, AT Le, RC Doebele Cancer discovery 5 (1), 25-34, 2015 | 637 | 2015 |
| An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101 RC Doebele, LE Davis, A Vaishnavi, AT Le, A Estrada-Bernal, S Keysar, ... Cancer discovery 5 (10), 1049-1057, 2015 | 410* | 2015 |
| RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer G Hrustanovic, V Olivas, E Pazarentzos, A Tulpule, S Asthana, ... Nature medicine 21 (9), 1038-1047, 2015 | 290 | 2015 |
| Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer KD Davies, S Mahale, DP Astling, DL Aisner, AT Le, TK Hinz, A Vaishnavi, ... PloS one 8 (12), e82236, 2013 | 162 | 2013 |
| EGFR mediates responses to small-molecule drugs targeting oncogenic fusion kinases A Vaishnavi, L Schubert, U Rix, LA Marek, AT Le, SB Keysar, ... Cancer research 77 (13), 3551-3563, 2017 | 77 | 2017 |
| TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015; 5: 25–34. doi: 10.1158/2159-8290 A Vaishnavi, AT Le, RC Doebele CD-14-0765.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 76 | |
| Organ-specific gene expression: the bHLH protein Sage provides tissue specificity to Drosophila FoxA RM Fox, A Vaishnavi, R Maruyama, DJ Andrew Development 140 (10), 2160-2171, 2013 | 39 | 2013 |
| NTRK1 gene fusions as a novel oncogene target in lung cancer. RC Doebele, A Vaishnavi, M Capelletti, AT Le, S Kako, M Butaney, ... Journal of Clinical Oncology 31 (15_suppl), 8023-8023, 2013 | 21 | 2013 |
| Inhibition of MEK1/2 forestalls the onset of acquired resistance to entrectinib in multiple models of NTRK1-driven cancer A Vaishnavi, MT Scherzer, CG Kinsey, GL Parkman, A Truong, P Ghazi, ... Cell reports 32 (5), 2020 | 17 | 2020 |
| TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015; 5: 25–34 A Vaishnavi, AT Le, RC Doebele PUBMED, 0 | 10 | |
| Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis A Vaishnavi, J Juan, M Jacob, C Stehn, EE Gardner, MT Scherzer, ... Cancer research 82 (22), 4261-4273, 2022 | 8 | 2022 |
| Analysis of NTRK1 gene fusion incidence in an unselected cohort of non-small cell lung cancer patients. RC Doebele, S Kako, AT Le, M da Costa Silva, A Vaishnavi, L Toschi, ... Journal of Clinical Oncology 32 (15_suppl), 8048-8048, 2014 | 4 | 2014 |
| Abstract A29: The CUTO panel of patient-derived NSCLC cell lines reveals unique molecular characteristics and responses to targeted therapies AT Le, A Estrada-Bernal, L Schubert, A Doak, N Chen, K Davies, ... Clinical Cancer Research 24 (17_Supplement), A29-A29, 2018 | 2 | 2018 |
| Adaptive Survival Signaling in Oncogenic Fusion Kinase Addicted NSCLC A Vaishnavi, SB Keysar, AT Le, DL Aisner, L Heasley, A Jimeno, ... JOURNAL OF THORACIC ONCOLOGY 10 (9), S214-S214, 2015 | 1 | 2015 |
| BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape D Planchard, RE Sanborn, MV Negrao, A Vaishnavi, EF Smit npj Precision Oncology 8 (1), 90, 2024 | | 2024 |
| Preclinical Modeling of Pathway-Targeted Therapy of Human Lung Cancer in the Mouse A Vaishnavi, CG Kinsey, M McMahon Cold Spring Harbor Perspectives in Medicine 14 (1), a041385, 2024 | | 2024 |
| Transposon Mutagenesis Reveals RBMS3 as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis A Vaishnavi, J Juan, MT Scherzer, JE VanVeen, C Stehn, CS Hackett, ... bioRxiv, 2022.02. 28.482366, 2022 | | 2022 |
| Combined TRKA and MEK1/2 Inhibition Forestalls the Onset of Acquired Resistance in a New Preclinical Model of NTRK1+ Pancreatic Cancer A Vaishnavi, MT Scherzer, C Kinsey, I Garrido-Laguna, M McMahon Cancer Research 80 (16_Supplement), 3769-3769, 2020 | | 2020 |
| The CUTO panel of patient-derived NSCLC cell lines reveals unique molecular characteristics and responses to targeted therapies AT Le, A Estrada-Bernal, L Schubert, A Doak, N Chen, K Davies, ... CLINICAL CANCER RESEARCH 24 (17), 2018 | | 2018 |
Robert C. Doebele, MD, PhDUniversity of Colorado, Anschutz Medical CampusVerified email at cuanschutz.edu
